

## A new regulator of B cell development

October 11 2019, by Leigh MacMillan



3D rendering of a B cell. Credit: Blausen.com staff (2014). "Medical gallery of Blausen Medical 2014". WikiJournal of Medicine 1 (2). DOI:10.15347/wjm/2014.010. ISSN 2002-4436. CC BY-SA 4.0

Interleukin-33 (IL-33) drives inflammatory responses in allergic and nonallergic disease. Epithelial cells in the lungs, gastrointestinal tract and elsewhere release IL-33, which activates the ST2 receptor on immune cell targets.



In addition to the ST2-binding domain, IL-33 contains a nuclear chromatin-binding domain, suggesting that it may act inside cells that produce it. However, a cell-intrinsic role for IL-33 has not been established.

Matthew Stier, MD, Ph.D., Stokes Peebles, MD, and colleagues have now identified IL-33 expression, but not ST2 receptor expression, in developing B cells in the bone marrow (mature B cells produce antibodies). They demonstrated that IL-33 deficiency resulted in increased numbers of developing B cells.

The researchers detected IL-33 during early B cell development in humans and found reduced IL-33 expression in B cell chronic lymphocytic leukemia samples compared to healthy controls.

The findings reported in the Sept. 15 *Journal of Immunology* establish a cell-intrinsic role for IL-33 in early B cell development that is independent of the ST2 receptor.

**More information:** Matthew T. Stier et al. IL-33 Is a Cell-Intrinsic Regulator of Fitness during Early B Cell Development, *The Journal of Immunology* (2019). DOI: 10.4049/jimmunol.1900408

Provided by Vanderbilt University

Citation: A new regulator of B cell development (2019, October 11) retrieved 28 April 2024 from <u>https://medicalxpress.com/news/2019-10-cell.html</u>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.